Although clear guidance on the predictive significance of each ERBB2 alteration/coalteration/tumor type context is beyond the scope of this (and arguably any single) study, we sought to demonstrate that CGP provides more complete genomic information than the limited readout of HER2 ± overexpression/amplification provided by IHC/FISH. The gene discussed is ERBB2; the disease is neoplasm.